Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on HIV (Aug 2017)

Posted by Matt Breese on Aug 11, 2017

Find me on:

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Coverage for commercial formularies varies slightly across the 3 major HIV drug categories (Integrase, Protease and Transcriptase). While Integrase treatments are the most restrictive, most drugs face some form of reimbursement restrictions across each channel.

mmit-reality check-hiv-3q2017.png

Source: MMIT data as of Q3 2017

Trends:  Recent news related to HIV treatments reveals the physician and patient perspective on therapy. The results from a recent phase 3 trial shows promise when it comes to simplifying HIV combination therapies. Based on recent drug developments, a 2-product combination in development could be as effective as existing 3 or 4-product combinations. We've also called out before how HIV awareness is improving with the use of social media and advocacy groups. 

To read the full Reality Check on HIV treatments with key findings on clinical characteristics, HIV drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing